1. Stocks
    2. /
  2. Telix Pharmaceuticals (ASX: TLX)
    3. /

Telix Pharmaceuticals (ASX: TLX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Telix Pharmaceuticals Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Telix Pharmaceuticals (ASX: TLX)
    Latest News

    A man in his 30s with a clipped beard sits at his laptop on a desk with one finger to the side of his face and his chin resting on his thumb as he looks concerned while staring at his computer screen.
    Cheap Shares

    Could these ASX 200 losers be among the best shares to buy in 2026?

    | James Mickleboro

    Is the stage set for a big rebound from these shares this year?

    Read more »

    A man has a surprised and relieved expression on his face.
    Cheap Shares

    3 phenomenal ASX stocks that could double in 2026

    | James Mickleboro

    Analysts think these stocks could be dirt cheap after a difficult time in 2025.

    Read more »

    A man in a suit face palms at the downturn happening with shares today.
    Share Market News

    These are the 10 most shorted ASX shares

    | James Mickleboro

    Let's see which shares short sellers are targeting this week.

    Read more »

    a man clasps his hand to his forehead as he looks down at his phone and grimaces with a pained expression on his face as he watches the Pilbara Minerals share price continue to fall
    Share Fallers

    These were the worst performing ASX 200 shares in 2025

    | James Mickleboro

    Shareholders of these shares will be hoping for better in 2026.

    Read more »

    A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
    Broker Notes

    2 ASX shares experts think will smash the market in 2026!

    | James Mickleboro

    Big returns could be on the cards for investors with these shares according to analysts.

    Read more »

    A happy young couple lie on a wooden deck using a skateboard for a pillow.
    Growth Shares

    10 ASX shares I would buy in 2026

    | James Mickleboro

    I think these are among the best stocks to buy for an ASX share portfolio in the new year.

    Read more »

    A man points at a paper as he holds an alarm clock, indicating the ex-dividend date is approaching.
    Growth Shares

    In 2036, you will be glad you bought these ASX shares today

    | James Mickleboro

    Want to make long term investments? I think these shares could be top picks.

    Read more »

    Woman with a scared look has hands on her face.
    Share Market News

    These are the 10 most shorted ASX shares

    | James Mickleboro

    Let's see which shares short sellers are targeting this week.

    Read more »

    A man holds up a block from falling in a row of dominos.
    Value Investing

    2 ASX 200 shares down 30% or more that could be a new years buy

    | Aaron Bell

    I'm keeping a close eye on these struggling stocks.

    Read more »

    Beautiful young woman drinking fresh orange juice in kitchen.
    Healthcare Shares

    Telix shares storm higher on big US and China news

    | James Mickleboro

    Let's see why this biotech is getting attention on Monday.

    Read more »

    A man holds his head in his hands after seeing bad news on his laptop screen.
    Share Market News

    These are the 10 most shorted ASX shares

    | James Mickleboro

    Let's see which shares short sellers are targeting this week.

    Read more »

    Successful group of people applauding in a business meeting and looking very happy.
    Share Market News

    Telix Pharmaceuticals in focus with China trial success and FDA updates

    | Laura Stewart

    Telix Pharmaceuticals posts positive China Phase 3 results for Illuccix and advances its FDA applications.

    Read more »

    Frequently Asked Questions

    No, Telix does not pay dividends at this time. 

    Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.

    TLX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Telix Pharmaceuticals

    Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.

    Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe. 

    The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States. 

    Profile

    since

    Note